|
ATCC
human pca cell lines Human Pca Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human pca cell lines/product/ATCC Average 99 stars, based on 1 article reviews
human pca cell lines - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human pc3 metastatic pca cell line ![]() Human Pc3 Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human pc3 metastatic pca cell line/product/ATCC Average 99 stars, based on 1 article reviews
human pc3 metastatic pca cell line - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human du145 metastatic pca cell line ![]() Human Du145 Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human du145 metastatic pca cell line/product/ATCC Average 99 stars, based on 1 article reviews
human du145 metastatic pca cell line - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human 22rv1 primary pca cell line ![]() Human 22rv1 Primary Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human 22rv1 primary pca cell line/product/ATCC Average 99 stars, based on 1 article reviews
human 22rv1 primary pca cell line - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human lncap metastatic pca cell line ![]() Human Lncap Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human lncap metastatic pca cell line/product/ATCC Average 99 stars, based on 1 article reviews
human lncap metastatic pca cell line - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
resource source identifier human lncap metastatic pca cell line atcc crl ![]() Resource Source Identifier Human Lncap Metastatic Pca Cell Line Atcc Crl, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/resource source identifier human lncap metastatic pca cell line atcc crl/product/ATCC Average 99 stars, based on 1 article reviews
resource source identifier human lncap metastatic pca cell line atcc crl - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
pdo models human pca cell line c4 ![]() Pdo Models Human Pca Cell Line C4, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/pdo models human pca cell line c4/product/ATCC Average 98 stars, based on 1 article reviews
pdo models human pca cell line c4 - by Bioz Stars,
2026-05
98/100 stars
|
Buy from Supplier |
|
ATCC
human epithelial pca cell line du145 ![]() Human Epithelial Pca Cell Line Du145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human epithelial pca cell line du145/product/ATCC Average 99 stars, based on 1 article reviews
human epithelial pca cell line du145 - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
Journal: Cell Reports Methods
Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
doi: 10.1016/j.crmeth.2026.101370
Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
Article Snippet:
Techniques: In Vivo, In Vitro, Concentration Assay
Journal: Cell Reports Methods
Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
doi: 10.1016/j.crmeth.2026.101370
Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
Article Snippet:
Techniques: In Vivo, In Vitro, Concentration Assay
Journal: Cell Reports Methods
Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
doi: 10.1016/j.crmeth.2026.101370
Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
Article Snippet:
Techniques: In Vivo, In Vitro, Concentration Assay
Journal: Cell Reports Methods
Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
doi: 10.1016/j.crmeth.2026.101370
Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
Article Snippet:
Techniques: In Vivo, In Vitro, Concentration Assay
Journal: Bio-protocol
Article Title: Non-Enzymatic Isolation of Cancer-Associated Fibroblasts From Human Prostate Tumor Explants
doi: 10.21769/BioProtoc.5614
Figure Lengend Snippet: . The results indicate that collagen type I (col1a1) and vimentin are expressed in both healthy and cancer-associated fibroblasts (HPFs and CAFs), confirming their mesenchymal identity. Conversely, α-smooth muscle actin (α-SMA) is detected exclusively in CAFs, reflecting their activation compared to the HPFs. As expected, CD31 is exclusively expressed in endothelial cells (ECFCs), while E-cadherin and claudin are only detected in epithelial cells (DU145), in accordance with their role in epithelial junctions. HSP90 was used as a loading control to ensure equal protein content across samples. HPF and CAF were derived from three different explants. Note that α-SMA expression differs among the three CAF samples, reflecting inter-patient biological variability.
Article Snippet:
Techniques: Activation Assay, Control, Derivative Assay, Expressing